The US Food and Drug Administration’s new vaccine approval philosophy upends established regulatory practices and could put ...

Vaccine experts said the memo was irresponsible and omits key details about how officials arrived at the conclusion.

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...

The FDA is facing new questions after an internal memo raised concerns about pediatric vaccine risks, prompting scrutiny of ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

Nov 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Monday pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine for the second time and now expects it to ...

If you have ever wondered whether Novavax is undervalued, overhyped, or a hidden gem in the biotech space, you are definitely not alone. The stock recently ticked up 1.8% over the past week, but has ...

Moderna Inc. fell in premarket trading Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.